Two new studies identify promising pathways to treat chronic COVID-19
Philadelphia | June 6, 2023
Investigators report in The American Journal of Pathology on novel studies designed to increase understanding of the chronic and sometimes progressive phase of COVID-19 that may lead to effective treatment options
Early studies of COVID-19 focused on the acute phase of the disease. However, attention has now turned to the long-term consequences of the disease, which are also significant causes of morbidity and mortality. Two studies reported in The American Journal of Pathology(opens in new tab/window), published by Elsevier, seek to understand the drivers of the chronic and sometimes progressive phase of the disease and identify possible pathways for drug treatment.
The COVID-19 pandemic has highlighted the need to better understand both acute and chronic disease triggered by severe respiratory viral infection. The acute phase of disease with severe pneumonia and lung injury dominated early management efforts and research priorities. However, progressive and often long-term disease is also a significant cause of morbidity and mortality. A high percentage of patients with COVID-19 survived the acute infectious illness only to experience a considerable degree of organ dysfunction over a more prolonged period during and after initial hospitalization.
In the first study highlighted here, investigators deliver a roadmap for the pathogenesis of post-viral lung disease and the basis for a drug therapy for long-term COVID-19 and related post-viral conditions. In the second study, investigators used a hamster model of human COVID-19 to study the cause of coagulation abnormalities and microscopic indicators of pulmonary vascular damage associated with severe cases of COVID-19 in humans. Results showed indirect vascular damage, possibly secondary to immune dysfunction, to be a major contributor to vascular damage, suggesting that novel therapeutics targeting the dysregulated immune system may prove effective.
In the study led by Michael J. Holtzman, MD, Pulmonary and Critical Care Medicine, Department of Medicine, and Department of Cell Biology and Physiology, Washington University School of Medicine, Saint Louis, investigators examined a series of autopsies of patients performed long after COVID-19 onset.
Dr. Holtzman explained, “Our research was inspired by the pressing need to understand the COVID-19 crisis, and especially to define the cause of the disease. We examined a series of consecutive fatal cases that came to autopsy between 27 and 51 days after hospital admission. In each patient, we identified a stereotyped bronchiolar-alveolar pattern of lung remodeling with basal epithelial cell hyperplasia, immune activation, and mucinous differentiation. Remodeling regions also featured macrophage infiltration and apoptosis and a marked depletion of alveolar type 1 and 2 epithelial cells. This pattern was very similar to our experimental models of progressive lung disease after respiratory viral infection.”
Caption: Investigators analyzed a series of autopsies from patients with COVID-19 with late-stage lung disease at least 27 to 51 days after initial viral infection. The results reveal a bronchiolar-alveolar lung remodeling process that is characterized by i) basal epithelial cell hyperplasia and metaplasia with extension into former alveolar spaces; ii) colocalized depletion of alveolar types of epithelial cells normally found in these spaces; iii) epithelial stem progenitor cell differentiation to mucous cells with mucins characteristic of mucosal and submucosal locations; and iv) basal epithelial cell production of chemokine CXCL17 associated with lung monocyte-macrophage infiltration (Credit: “Lung Remodeling Regions in Long-Term Coronavirus Disease 19 Feature Basal Epithelial Cell Reprogramming,” by Kangyun Wu, et al., TheAmerican Journal of Pathology).
The investigators noted several key scientific impacts based on identifying remodeling regions with basal epithelial cell hyperplasia and metaplasia extending into former alveolar spaces; concomitant dropout of both types of alveolar epithelial cells normally found in these spaces; epithelial stem-progenitor cell differentiation to mucous cells with a mixture of mucosal and submucosal types of mucin production; and macrophage infiltration linked to basal epithelial cell-specific chemokine production.
Dr. Holtzman commented, “Taken together with the results of our previously published animal models of post-viral lung disease, these studies deliver a roadmap for the pathogenesis of post-viral lung disease and the basis for a disease-modifying strategy for long-term COVID-19 and related post-viral conditions. The research defines a pattern of disease that implicates specific cell and molecular targets for therapy. Indeed, we are now developing a drug therapy that aims precisely at fixing those targets.”
As the pandemic progressed, physicians frequently reported clinical evidence of coagulation abnormalities and microscopic indicators of pulmonary vascular damage associated with severe human cases of COVID-19, noted Erin E. Ball, DVM, PhD, Department of Pathology, Microbiology, and Immunology, University of California, Davis, and colleagues. A team of investigators led by Dr. Ball injected severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) that causes COVID-19 into a Syrian golden hamster model of human COVID-19 to determine the cause of pulmonary vascular damage. At three to seven days post inoculation, they detected SARS-CoV-2 antigen and RNA within airway epithelial cells, pneumocytes, and macrophages, but not associated with blood vessels.
Their results showed that regions of active pulmonary inflammation in SARS-CoV-2 infection were characterized by ultrastructural evidence of endothelial damage with platelet marginalization and perivascular and subendothelial macrophage infiltration. SARS-CoV-2 antigen or RNA was not detectable within affected blood vessels. The investigators had initially assumed the prominent microscopic vascular lesions noted in hamsters between three and seven days post SARS-CoV-2 inoculation would be the result of direct viral infection of cells comprising blood vessels; however, this was not the case.
Caption: (A) Lung tissue section from a SARS-CoV-2-inoculated hamster euthanized (6 days post infection (dpi). There is prominent mononuclear endotheliitis (arrows) with perivascular inflammation. Hematoxylin and eosin (H&E) stain (Credit: Erin Ball with slide scanning by M. Kevin Keel). (B) Transmission electron microscopy (TEM) images of a hamster pulmonary blood vessel six days after inoculation with SARS-CoV-2. There are damaged, degenerating endothelial cells (EC) with marked cytoplasmic vacuolation (asterisks). RBC = red blood cell; scale bar (A) = 20 µm; scale bar (B) = 2 µm (Credit: Bradley Shibata, “Severe Acute Respiratory Syndrome Coronavirus 2 Vasculopathy in a Syrian Golden Hamster Model,” by Erin E. Ball, et al., The American Journal of Pathology).
Dr. Ball added,“These findings suggest that indirect vascular damage, possibly secondary to immune dysfunction, is a major contributor to vascular damage observed in SARS-CoV-2-inoculated hamsters and potentially severe COVID-19 infection in humans. Immune dysregulation resulting in excessive production of pro-inflammatory cytokines, endothelial damage, and platelet hyperactivation is a plausible driving force behind the hypercoagulable state and microthrombosis observed in some COVID-19 patients.”
Although this was an observational study, these findings, and particularly the lack of viral association with inflamed vessels together with published data, collectively support a primarily indirect mechanism linking inflammation and hypercoagulability in severe cases of COVID-19. These results suggest that novel therapeutics targeting the dysregulated immune system may prove effective medical countermeasures against COVID-19.
Notes for editors
The articles are: “Lung Remodeling Regions in Long-Term Coronavirus Disease 2019 Feature Basal Epithelial Cell Reprogramming,” by Kangyun Wu, Yong Zhang, Stephen R. Austin, Huqing Yin Declue, Derek E. Byers, Erika C. Crouch, and Michael J. Holtzman (https://doi.org/10.1016/j.ajpath.2023.02.005(opens in new tab/window)). The article is openly available at https://ajp.amjpathol.org/article/S0002-9440(23)00056-1/fulltext(opens in new tab/window).
The study was supported by NIH National Heart, Lung, and Blood Institute grant R35-HL145242 and National Institute of Allergy and Infectious Diseases grant R01-AI130591, Department of Defense TTDA grants W81XWH2010603 and W81XWH2210281, Harrington Discovery Institute, Cystic Fibrosis Foundation, Bebermeyer Hardy, and Schaefer Funds.
Contact for interviews: Michael J. Holtzman, MD, at [email protected](opens in new tab/window), or Julia Evangelou Strait, WashU Medicine Marketing & Communications, Washington University School of Medicine in St. Louis, at +1 314 286 0141; [email protected](opens in new tab/window)
“Severe Acute Respiratory Syndrome Coronavirus 2 Vasculopathy in a Syrian Golden Hamster Model,” by Erin E. Ball, Christopher M. Weiss, Hongwei Liu, Kenneth Jackson, M. Kevin Keel, Christopher J. Miller, Koen K.A. Van Rompay, Lark L. Coffey, and Patricia A. Pesavento (https://doi.org/10.1016/j.ajpath.2023.02.013(opens in new tab/window)). The article is openly available at https://ajp.amjpathol.org/article/S0002-9440(23)00082-2/fulltext(opens in new tab/window).
The study was supported by the Center for Immunology and Infectious Diseases, University of California, Davis, intramural funding; NIH grant R01-AI118590; the Graduate Student Support Program, University of California, Davis; and the US Army Medical Center of Excellence Long Term Health Education and Training Program.
Contact for interviews: Erin E. Ball, DVM, PhD, at [email protected](opens in new tab/window)
The articles appear online in The American Journal of Pathology, volume 193, issue 6 (June 2023), published by Elsevier.
Full text of the articles is also available to credentialed journalists upon request. Contact Eileen Leahy at +1 732 238 3628 or [email protected](opens in new tab/window) to request PDFs of the articles.
About The American Journal of Pathology
The American Journal of Pathology(opens in new tab/window), official journal of the American Society for Investigative Pathology(opens in new tab/window), published by Elsevier, seeks high-quality original research reports, reviews, and commentaries related to the molecular and cellular basis of disease. The editors will consider basic, translational, and clinical investigations that directly address mechanisms of pathogenesis or provide a foundation for future mechanistic inquiries. Examples of such foundational investigations include data mining, identification of biomarkers, molecular pathology, and discovery research. High priority is given to studies of human disease and relevant experimental models using molecular, cellular, and organismal approaches. https://ajp.amjpathol.org(opens in new tab/window)
As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, academic leaders, funders, R&D-intensive corporations, doctors, and nurses.
Elsevier employs 9,000 people worldwide, including over 2,500 technologists. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, medical education, and nursing education. Researchers and healthcare professionals rely on over 2,800 journals, including The Lancet(opens in new tab/window) and Cell(opens in new tab/window); 46,000+ eBook titles; and iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation(opens in new tab/window) and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.
Elsevier is part of RELX(opens in new tab/window), a global provider of information-based analytics and decision tools for professional and business customers.